“…For example, compounds 29, 30, and 31 showed good inhibitory activities against PI3Kδ and also exhibited remarkable anti-inflammatory activities. At this stage, those compounds with slight toxicity (cell viability below 80% at 10 μM) were excluded for further tests (Figure S1), 13 including compounds 23,26,33,34,38,39, and 42−46. Next, we took together the PI3Kδ potency, anti-inflammatory activity, and toxicity, and selected compounds 29, 30, 31, and 36 as promising candidates for further multidose evaluation.…”